Kuaishou Technology (LON:0A74)
77.00
0.00 (0.00%)
At close: Aug 4, 2025
Verve Therapeutics Revenue
Kuaishou Technology had revenue of 32.61B CNY in the quarter ending March 31, 2025, with 10.88% growth. This brings the company's revenue in the last twelve months to 130.10B, up 10.57% year-over-year. In the year 2024, Kuaishou Technology had annual revenue of 126.90B with 11.83% growth.
Revenue (ttm)
130.10B CNY
Revenue Growth
+10.57%
P/S Ratio
2.36
Revenue / Employee
5.26M CNY
Employees
24,718
Market Cap
32.79B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 126.90B | 13.43B | 11.83% |
Dec 31, 2023 | 113.47B | 19.29B | 20.48% |
Dec 31, 2022 | 94.18B | 13.10B | 16.16% |
Dec 31, 2021 | 81.08B | 22.31B | 37.95% |
Dec 31, 2020 | 58.78B | 19.66B | 50.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
HSBC Holdings | 41.03B |
Shell | 198.54B |
Unilever | 51.24B |
British American Tobacco p.l.c. | 25.60B |
Rolls-Royce Holdings | 19.54B |
Rio Tinto Group | 39.22B |
RELX PLC | 9.53B |